Manufacturer record
MANKIND PHARMA LTD. Doring Block: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by MANKIND PHARMA LTD. Doring Block (Sikkim) were declared Not of Standard Quality between August 2023 and September 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: Q15Y005, Olmesartan Medoxomil Amlodipine & Hydrochlorothiazide Tablets (exp Nov 2027). LUCKNOW, Uttar Pradesh (state lab) found it not of standard quality: The sample does not conform to declared formula, in respect of content of Olmesartan Medoxomil and Amlodipine. Listed in the September 2026 alert.
Records by type
2 records linked to MANKIND PHARMA LTD. Doring Block in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Olmesartan Medoxomil Amlodipine & Hydrochlorothiazide Tablets | Batch Q15Y005Mfg Dec 2025 · Exp Nov 2027 | The sample does not conform to declared formula, in respect of content of Olmesartan Medoxomil and Amlodipine.Other | LUCKNOW, Uttar PradeshState lab | Sep 2026 |
| Metformin Hydrochloride Prolonged Release and Glimepiride Tablets IP (GLIMESTAR� M2 FORTE) | Batch P9IAV007Mfg Nov 2022 · Exp Oct 2024 | Disintegration and DissolutonDisintegration | RDTL GuwahatiState lab | Aug 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.